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SELECTIVE PARP-l TARGETING FOR 
DESIGNING CHEMO/RADIO SENSITIZING 
AGENTS 
CLAIM OF PRIORITY 
This application claims priority from US. provisional 
patent application Ser. No. 60/296,110, ?led Jun. 7, 2001. 
FIELD OF THE INVENTION 
The invention relates generally to cancer treatment, and in 
particular to overcoming cellular resistance to antitumor 
agents. 
BACKGROUND OF THE INVENTION 
DNA repair is a mechanism of resistance to antitumor 
DNA damaging agents and to radiotherapy. Rosen EM et al., 
Cancer Invest. 17(1): 56472 (1999). The ability of cancer 
cells to recogniZe and repair DNA damage in?icted by 
cancer therapy is an important mechanism of resistance to 
treatment. Thus, inhibition of DNA repair is a key strategy 
in enabling cancer therapy. 
Activation of the poly(ADP-ribose) polymerase-1 
(PARP-l) enZyme is an immediate cellular response to 
genotoxic stress and is part of a genomic surveillance 
mechanism that responds to DNA damage, triggering sig 
naling events that can lead to cellular recovery. PARP-l is 
speci?cally activated by binding to DNA strand breaks. 
PARP-l has been shoWn to be a target for the development 
of radio and chemo sensitizing agents in cancer treatment as 
Well as providing protection from stroke. SZabo C & DaW 
son V L, Trends Pharmacol Sci. 19(7): 287498 (1998). 
Current inhibitors target a conserved catalytic domain of 
poly(ADP-Ribose) polymerase-1 (PARP-l) present in all of 
the PARP family members. Ruf A. et al., Biochemistry 
37(11): 38934900 (1998); Tentor‘i L et al., Pharmacol Res. 
45(2): 73485 (2002); Jacobson M K & Jacobson E L, Trends 
Biochem Sci. 24(11): 41547 (1999). 
Knockout experiments have shoWn that the therapeutic 
bene?ts of PARP-l inhibition are a direct result of the 
selective inhibition of PARP-l. Shall S & de Murcia G, 
Mural. Res. 4601: 1415 (2000). Although PARP-l knockout 
is not lethal, it leads to genomic instability and enhances the 
cytotoxicity of DNA damaging agents used in cancer 
therapy. Several PARP-l inhibitors are currently in preclini 
cal development for cancer therapy. Each of these inhibitors 
targets the binding site of the required substrate of the 
enZyme, nicotinamide adenine dinucleotide (NAD). WhiteA 
W et al., J. Med. Chem. 43: 4084497 (2000). 
Until recently, PARP-l Was the only knoWn enZyme With 
ADP-ribose polymerizing activity. PARP-l has noW been 
found to be one of a family of enZymes With PARP activity. 
Jacobson M K & Jacobson E L, Trends Biochem. Sci. 24: 
41547 (1999). Amino acid sequence comparisons of the 
members of the PARP family indicate that there is similarity 
in their NAD binding sites (pADPRT domain, see, FIG. 1A). 
Thus, the current inhibitors lack selectivity, because they 
target an NAD binding site common to all PARP family 
members. 
A double knockout of PARP-l and PARP-2 results in an 
embryonic lethal. Schreiber V. et al., J. Biol. Chem. (2002). 
PARP-l inhibitors have also inhibit PARP-2, thus it is likely 
that the current strategy of inhibitor design may lead to toxic 
effects. Perkins E. et al., Cancer Res. 61(10): 4175483 
(2001). 
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Thus, While PARP-l remains a promising therapeutic 
target, the discovery of multiple PARPs raises questions of 
inhibitor selectivity not heretofore considered. 
SUMMARY OF THE INVENTION 
The invention provides the identi?cation of a Src-homol 
ogy 3 (SH3) domain (domain C; SEQ ID NO: 1) and an SH3 
ligand domain (PXXP motif) (SEQ ID NO: 2) on the 
poly(ADP-ribose) polymerase-1 (PARP-l) protein (SEQ ID 
NOS: 4 and 6). The invention also provides that these 
domains are involved in PARP-l activation. The mechanism 
of PARP-l activation resembles that of src-tyrosine kinase 
activation. Accordingly, the invention provides neW meth 
ods for selectively targeting the SH3 domain of PARP-l. 
The overall importance of this invention is a neW under 
standing of the structural mechanisms of enZymes involved 
in poly ADP-ribosylation and the utiliZation of this neW 
information in the design of selective inhibitors of the 
PARP-l enZyme. Thus, the invention involves a paradigm 
shift in the design of inhibitors for this anticancer target. 
In one embodiment, the invention provides a method for 
identifying agents that activate PARP-l, including the steps 
of: 
(a) contacting a test compound With PARP-l or a func 
tional fragment thereof, Wherein the functional frag 
ment contains the PARP-l SH-3 domain, the PARP-l 
SH3-ligand domain, or both domains; 
(b) assaying Whether contacting the compound results in 
activation of PARP-l; and 
(c) identifying the test compound as a compound that 
activates PARP-l. 
In another embodiment, the invention provides a method 
for identifying agents that inactivate PARP-l, including the 
steps of: 
(a) contacting a test compound With PARP-l or a func 
tional fragment thereof, Wherein the functional frag 
ment contains the PARP-l SH-3 domain, the PARP-l 
SH3-ligand domain, or both domains; 
(b) assaying Whether contacting the compound results in 
inactivation or prevents activation of PARP-l; and 
(c) identifying the test compound as a compound that 
inactivates or prevents activation of PARP-l. 
In yet another embodiment, the invention provides a 
method for designing PARP-l inhibitors, including the steps 
of 
a) providing the structure of the PARP-l SH-3 domain or 
the PARP-l SH3 -ligand domain in a digital format that 
can be used by a molecular modeling computer pro 
gram; 
(b) obtaining the structure of a compound suspected of 
molecularly interacting With the PARP-l SH-3domain 
or the PARP-l SH3-ligand domain; 
(c) providing the structure of the compound suspected of 
molecularly interacting With the PARP-l SH-3 domain 
or the PARP-l SH3-ligand domain in a digital format 
that can be used by the molecular modeling computer 
Program; 
(d) operating the molecular modeling computer program 
to determine 
(i) Whether the PARP-l SH-3 domain molecularly 
interacts With the compound suspected of molecu 
larly interacting With the PARP-l SH-3 domain, or 
(ii) Whether the PARP-l SH3-ligand domain molecu 
larly interacts With the compound suspected of 
molecularly interacting With the PARP-l SH3-ligand 
domain; and 
US 7,072,771 B2 
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(e) identifying a compound that interacts molecularly as a 
potential therapeutic agent. 
In a speci?c embodiment, small peptides With the 
sequence RIAPEAPV (SEQ ID NO: 7) compete With the 
natural ligand of PARP-1 protein to affect PARP-1 activity. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a set of graphic representations of enZymes in the 
PARP family. FIG. 1A shoWs the overall domain organiZa 
tion of PARP family members, PARP-1 (SEQ ID NOS: 4 
and 6); PARP-2 (SEQ ID NOS: 9 and 11); PARP-3 (SEQ ID 
NO: 13); tankyrase (SEQ ID NO: 15) and vault-PARP (SEQ 
ID NO: 17). All PARPs contain a conserved poly ADP 
ribosylation domain. Some also contain a DNA binding 
domain (A, A', A") and protein interaction domains (D, G). 
The conserved ADPRT-fold also found in bacterial toxins 
(domain F) is shoWn in the ribbon diagram of the structure 
of CF-PARP-l. As provided in this invention, PARP-1 
contains a SH3 domain (C) and SH3 ligand. FIG. 1B shoWs 
the activation mechanism of PARP-1 described in this 
application, involving the formation of a PARP-1 
homodimer through the intermolecular interaction of an SH3 
and SH3 ligand domains. 
FIG. 2 is a pictorial description of the ADP-ribose poly 
mer cycle. Polymer biosynthesis involves the action of 
PARP-1, Which utiliZes NAD. ADP-ribose polymers are 
short lived and degraded by poly(ADP-ribose) glycohydro 
lase (PARG). 
FIG. 3 is a ribbon draWing of the catalytic fragment of 
PARP-1 (CF-PARP-l). The N-terminal all alpha domain is 
on the left side of the ?gure and the ADP-ribosyltransferase 
domain or ADPRT on the right. The all alpha domain forms 
a pocket for the binding of the adenine portion the NAD 
substrate (also knoWn as the donor site). The ADPRT fold 
binds the acceptor site or elongating poly(ADP-ribose) 
polymer. The PXXP SH3 ligand (SEQ ID NO: 2) lies in a 
loop at the interface betWeen the all alpha domain and the 
ADPRT fold. The gain of function mutation L613F (SEQ ID 
NO: 18) maps to the all alpha helical domain right at the 
interface Where the PXXP motif is localiZed. 
FIG. 4 shoWs the structure of CF-PARP-l and its inhibitor 
complexes. The NAD substrate binding site (donor site) With 
the adenine moiety binding is in a deep pocket, While the 
nicotinamide portion is localiZed in a shalloW pocket next to 
the terminal ADP-ribose unit of the polymer (acceptor site). 
FIG. 5 is a diagram of the tertiary structure of a typical 
SH3 module, shoWing the surface responsible for recogni 
tion of the PXXP ligand. TWo clusters of aromatic residues 
in the sequence form the peptide-binding surface. The 
conserved YDF motif (SEQ ID NO: 19) is found at the 
N-terminal end of the SH3 sequence at the beginning of the 
?rst loop (also knoWn as RT-loop). The WXXPXXY motif 
(SEQ ID NO: 20) is found at the C-terminal end just before 
the very last strand. The tWo loops surrounding the peptide 
binding surface contribute to the speci?city of the interac 
tion. 
FIG. 6 is a sequence alignment of a select group of SH3 
domains (top 7 sequences) Whose structures have been 
determined and deposited in the PDB database (?rst three 
letters of the sequence identi?cation indicates the PDB 
code): 1AEY (SEQ ID NO: 21); 1AOJ_A (SEQ ID NO: 22); 
1AZE_A (SEQ ID NO: 23); 1AON_B (SEQ ID NO: 24); 
1ABO_A (SEQ ID NO: 25); 1ARK (SEQ ID NO: 26); 
P53BP (SEQ ID NO: 29). The bottom 6 sequences are those 
from the C domain of PARP-1 from mouse (P_mussh3; SEQ 
ID NO: 28), rat (P_ratsh3; SEQ ID NO: 29), human 
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(P_humsh3; SEQ ID NO: 30), bovine (P_bovsh3; SEQ ID 
NO: 31), chicken (P_chksh3; SEQ ID NO: 32) and Xenopus 
(P_xensh3; SEQ ID NO: 33). 
DETAILED DESCRIPTION OF THE 
INVENTION 
PARP-1 and the unique post-translational modi?cation it 
catalyZes have previously been considered to function only 
in the cellular surveillance of genotoxic stress. HoWever, the 
recent identi?cation of multiple members of a PARP family 
might force a revision and expansion of this concept. 
PARP-1 is a unique 114 kDa multidomain biosensor that 
recogniZes DNA strand breaks introduced in the genome of 
eukaryotic cells exposed to radiation or genotoxic agents. 
The recognition of DNA nicks by tWo Zinc ?ngers domains 
of PARP-1 (domain A, FIG. 1), found at its N-ter'minus, 
triggers the activity of the catalytic of CF-PARP-l (domain 
E+F, FIG. 1) by 500-fold. PARP-1 attaches ADP-ribose 
(ADPR) to itself (domain D, FIG. 1A) and a groWing array 
of nuclear protein acceptors using nicotinamide adenine 
dinucleotide (NAD) as a substrate. PARP-1 synthesiZes 
ADP-ribose polymers from NAD+ by attaching NAD+ to 
glutamic acid of acceptor proteins such as histones, P53 and 
proteins involved in the formation of DNA repair com 
plexes, such as the Base Excision repair complex (BASC), 
DNA pol[3 and XRCC1. The NAD is covalently linked to the 
terminal ADP-ribose moiety of the elongating ADP-ribose 
polymer. RufA et al., Proc. Natl. Acad. Sci. USA 93(15): 
74815 (1996). 
The active site of all PARPs contain a conserved glutamic 
acid residue Which enables a nucleophilic attack on the 
glycosidic bond to the nicotinamide portion of NAD by the 
2' hydroxyl of the terminal ADPR unit of the terminal 
polymer. The adenine portion of NAD binds in a deep pocket 
of the CF-PARP-l structure, While the nicotinamide portion 
of NAD binds in a shalloW cavity. 
The use of NAD+ as a substrate by PARP-1 establishes a 
link betWeen poly ADP-ribosylation and the energy status of 
the cell. In situations of massive DNA damage, PARP-1 is 
hyperactivated. NAD+ depletion folloWs, resulting in cellu 
lar necrosis. Thus, regulation of PARP-1 activity is at a 
crucial intersection in the cellular fate. 
The observation that there is essentially no detectable 
poly(ADP-ribose) in resting cells suggests that PARPs are 
generally inactive and, therefore, tightly regulated in vivo. 
Smith S, Trends Biochem. Sci. 26: 174*179 (2001). 
Cancer cells are able to evade programmed cell death 
(apoptosis) by a mechanism that involves PARP-1 inactiva 
tion through cleavage by Caspase-3. Smulson M E et al., 
Adv. Enzyme Regul. 40: 183*215 (2000). Consequently, 
cancer cells retain the ability to signal DNA repair in 
response to single strand breaks. PARP-1 inhibition in 
cancer cells mimics its apoptotic inactivation and disables 
recovery of cancer cells exposed to radiologic or chemo 
therapeutic agents. 
Current inhibitors of PARP-1 have targeted the catalytic 
fragment of PARP-1, Which contains an NAD binding site. 
Bousquet J A et al., Biochemistry 39: 7722*35 (2000). The 
current inhibitors of PARP-1 are derivatives of benZamides 
and fused ring heterocycles that bind to the nicotinamide 
cavity and inhibit PARP-1 by competing With NAD sub 
strate. US. Pat. Nos. 6,201,020, 6,121,278, 5,587,384, 
5,215,738; 5,041,653 and 5,032,617. HoWever, because all 
PARPs contain this conserved binding, the current PARP-1 
inhibitors lack selectivity. 
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This invention addresses this selectivity issue by provid 
ing an understanding of the mechanism of PARP-l activa 
tion, at the molecular level. As described below, the inven 
tion puts forWard the involvement of an SH3 domain 
(domain C, FIG. 1; SEQ ID NO: 1) and an SH3-ligand 
domain (PXXP motif; SEQ ID NO: 2). 
This invention provides a paradigm shift in the design of 
PARP-l inhibitors, Where the molecular target is a protein 
interaction interface involved in triggering PARP-l activity 
once PARP-l recogniZes damaged DNA, rather than the 
NAD+ binding site, Where all current inhibitor effort has 
been focused. As described beloW, PARP-l activation result 
ing from DNA strand break recognition results from the 
action of an SH3 protein interaction module on PARP-l that 
potentiates the catalytic dimer. Accordingly, the present 
invention provides for the development of a neW drug 
discovery paradigm for generation of PARP-l inhibitors for 
cancer therapy, by affecting function by allosteric mecha 
nisms. DeDecker B S, Chem. Biol. 7(5): Rl03i7 (2000). 
Poly(ADP-ribose) polymerase-1 (PARP-l) is a Key Bio 
synthetic Target for Drug Discovery. The PARP-l enZyme 
has been puri?ed and the gene has been characterized. 
Cherney B W et al., Proc. Natl. Acad. Sci. USA 84(23): 
837044 (1987); Kurosaki T et al., J. Biol. Chem. 262(33): 
1599047 (1987); Uchida K et al., Biochem. Biophys. Res. 
Commun. 148(2): 617422 (1987); Auer B et al., DNA 8(8): 
575480 (1989). The availability of this information led to 
further developments: (1) structural and site directed 
mutagenesis studies enabling the de?nition of several func 
tional domains including tWo Zinc ?nger domains at the 
N-terminal (FIG. 1A) that bind to DNA strand breaks, an 
internal automodi?cation domain similar to that found in the 
C-terminus of the breast cancer gene (BRCT domain), and 
a C-terminal catalytic fragment containing a conserved 
NAD"; (2) the generation of PARP-l “knockout” mice that, 
despite having a normal development and the capability of 
generating ADPR polymers, are very sensitive to genotoxic 
stress and have a shorter life span; (3) the detection of the 
cleavage of PARP-l by caspases at the DED sequence motif 
found at the very end of the Zinc ?nger domain (Nicholson, 
D W et al., Nature 376(6535): 37443 (1995)); (4) the 
structural determination of the catalytic domain of PARP-l 
(CF-PARP-l) (Ruf, A et al., Proc. Natl. Acad. Sci. USA 
93(15): 748145 (1996)), Which has structural homology to 
the ADP-ribosyl transfer (ADPRT) domain of diphtheria, 
cholera, pertussis and enterotoxins; and (5) the identi?cation 
of PARP-l inhibitors, targeting the shalloW nicotinamide 
pocket, and used in cancer therapy as radio and chemosen 
sitiZing agents. White A W et al., J. Med. Chem. 43(22): 
4084497 (2000); Schlicker A et al., Int. J. Radial. Biol. 
75(1): 914100 (1999)). 
Thus, PARP-l functions as a cellular biosensor of DNA 
strands breaks, triggering the poly ADP-ribosylation of 
chromatin and DNA repair proteins. The recognition of 
strand breaks results in at least a 200-fold increase in 
enZyme activity. The catalytic domain serves tWo functions: 
(1) automodi?cation of PARP at conserved glutamate resi 
dues localiZed in the BRCT domain, through the formation 
of dimers. MendoZa-AlvareZ H & AlvareZ-GonZaleZ R, J. 
Biol. Chem. 268(30): 22575480 (1993); and (2) the ADP 
ribosylation of other protein acceptors including histones 
and DNA-repair complexes. The ADP-ribosylation of his 
tones by PARP is thought to be an important step in 
chromatin decondensation, Which may be part of an overall 
mechanism of freeing the damaged DNA While at the same 
time recruiting the action of DNA repair complexes. 
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PARP-l is a Member of a NeW Family of Poly ADP 
Ribosylating Proteins. The development of PARP-l knock 
out mice revealed that polymer metabolism Was not dis 
rupted in PARP-l knockout mice. Shieh W M et al., J. Biol. 
Chem. 273(46): 30069472 (1998). This information sug 
gested functional redundancy in the production of poly 
(ADP-ribose). TWo closely related PARPs (PARP-2 (SEQ 
ID NOS: 9 and 11) and PARP-3 (SEQ ID NO: 13)) Were 
identi?ed in human and Drosophila. Johansson M, Genom 
ics 57(3): 4425 (1999); Ame J C et al, J. Biol. Chem. 
274(25): 1786048 (1999); KaWamura T et al., Biochem. 
Biophys. Res. Commun. 251(1): p. 35410 (1998). 
The ?rst neW PARP member identi?ed Was tankyrase 
(Smith S et al., Science 282(5393): 148447 (1998)), also a 
multidomain protein containing the protein interaction mod 
ules ankyrin repeats and SAM domains (SEQ ID NO: 15). 
Tankyrase is responsible for the ADP-ribosylation of TRF1, 
a protein involved in the assembly and disassembly of the 
T-loop structure found at the ends of the chromosomes. 
Tankyrase serves to regulate the function of TRF1 and thus, 
is a potentially neW target for inhibiting the action of 
telomerase in cancer cells. 
The second neW member of the PARP family identi?ed 
Was vault PARP (SEQ ID NO: 17). Kickhoefer VA et al., J. 
Cell Biol. 146(5): 917428 (1999). Vault PARP is also a 
multidomain protein containing the BCRT protein interac 
tion domain, present in PARP-l and several DNA repair 
proteins. Vault PARP is a large protein-RNA complex found 
in the cytoplasm, and currently thought to mediate the 
transport of mRNA. 
The single conserved domain found in all PARPs is a 
catalytic fragment of PARP-l (CF-PARP-l). The structure 
of CF-PARP-l Was recently determined by Ruf et al., Proc. 
Natl. Acad. Sci. USA 93(15): 74815 (1996), and revealed a 
conserved ADP-ribosyltransferase domain (ADPRT, domain 
F) core structure also found in bacterial toxins. Like 
ADPRTs, PARP contains an NAD+ recognition site. A 
detailed comparison of the structure of PARP With the toxins 
shoWed a conserved catalytic glutamic acid at the beginning 
of the ?fth stand ([35) of the ADPRT fold (see, FIG. 4). 
PARP Activation Requires Self-association. The relation 
ship betWeen the oligomeric state of PARP-l and its acti 
vation has been investigated by several techniques, includ 
ing sedimentation equilibrium, gel permeation, 
electrophoretic mobility and kinetics measurements. Juarez 
Salinas H et al., Anal. Biochem. 131(2): 41048 (1983). 
PARP-l in its activated form is a homodimer, but the 
structural elements required for dimeriZation remain 
unknoWn. The presence of the protein interaction domain, 
BRCT, suggests that BRCT may potentiate dimeriZation. 
BRCT domains are found in several DNA repair proteins 
leading to the formation of the BRCA-associated genome 
surveillance complex or BASC and the DNA-base excision 
complex (BEC). PARP-l may have a regulatory/assembly 
function in the formation of these complexes through ADP 
ribosylation. 
The structure of Drosophila PARP-l suggested that 
PARP-l protein interactions occurred through a conserved 
leucine Zipper at the N-terminus of the BRCT domain. 
Uchida K et al., Proc. Natl. Acad. Sci. USA 90(8): p. 348145 
(1993). Evidence in support of this model include: (1) the 
C-terminal apoptotic cleavage product (lacking only the Zinc 
?nger domains) inhibits dimeriZation and consequently 
PARP-l activation (Kim, J W et al., J. Biol. Chem. 275(11): 
81215 (2000)); and (2) deletion mutant analyses of PARP-l 
have been used to map the dimeriZation domain to the 
vicinity of the BRCT domain containing the putative leucine 
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Zipper motif. The recent structural determination of the 
BRCT domain of XRCC1 (Marintchev A et al., Nat. Slrucl. 
Biol. 6(9): 884e93 (1999)) and sequence alignment of the 
BRCT family, including PARP-1-BRCT (Bork P et al., 
FASEB J. 11(1): 68e76 (1997)), maps the putative leucine 
Zipper motif to a surface-exposed N-terminal helix (otl) of 
this ot/[3 structure. In the crystal structure of XRCC1, the 
BRCT domain helix al was found to be involved in 
homodimeriZation and Was proposed to mediate protein 
interactions in vivo. 
SH3 Protein Interaction Modules and Enzyme Activation. 
Many proteins, including the src family of tyrosine kinases, 
are regulated by the interaction of SH3 and SH3-ligand 
domains. Dalgamo D C et al. Biopolymers 43: 383e400 
(1997). 
Cells use protein interaction modules (SH2, SH3, EH, 
PDZ, WW, PTB) in the recruitment of active molecules into 
multiprotein signal complexes or in the activation of dor 
mant enZymes. One of these interaction modules is the SH3 
domain that binds to proline-rich peptide sequences With the 
consensus sequence, PXXP (SEQ ID NO: 2), Which forms 
a left-handed polyproline type II helix (PPII). Kuriyan J & 
CoWbum D, Annu. Rev. Biophys. Biomol. Slrucl. 26: 259*88 
(1997). The name SH3 stands for the conserved Src-homol 
ogy domain 3 found in Src-family tyrosine kinases. Along 
With the SH2 domain, SH3 domains regulate the activation 
and the localiZation targeting of Src-kinases. Williams J C et 
al., Trends Biochem. Sci. 23(5): 179*84 (1998). The SH3 
domain is a small (~60 residues) domain With over 250 
representative sequences in the SWISSPROT database 
(SEQ ID NO: 1). All SH3 domains fold into a compact 
structure made up of tWo anti-parallel beta sheets of four 
stands connected by loops of varying siZes (RT-loop and 
n-src loop, see, FIG. 4). The general peptide-binding surface 
of the SH3 module is made up of a cluster of aromatic 
residues, forming three pockets. The tWo prolines of the core 
motif PXXP (the SH3-ligand; SEQ ID NO: 2) bind to tWo 
hydrophobic pockets containing conserved aromatic resi 
dues, While a third pocket is usually lined up With negative 
charges and usually interacts With a positively charged 
residue of the ligand. Kardinal C et al., Ann. NY Acad. Sci. 
886: 289e92 (1999). 
PARP-1 contains an SH3 domain and an SH3-ligand 
domain. During an analysis of an alignment of several PARP 
sequences, We found that PARP-1 contains a previously 
unknown SH3 domain (SEQ ID NO: 30) and a previously 
unknown SH3-ligand domain (SEQ ID NO: 34). FIG. 1A 
shoWs the location of the predicted SH3 and SH3-ligand 
domains in PARP-1 and shoWs that these domains are not 
present in the other members of the PARP family of proteins. 
From this analysis, the CF-fragment of PARP-1, Whose 
structure had been determined, Was found to contain a PXXP 
sequence localiZed Within a surface accessible loop, Which 
leads to the active site of PARP-1 (FIG. 3 and FIG. 5). The 
sequence contained a conserved arginine residue (R778, 
human sequence; SEQ ID NO: 4) found at the N-terminal 
end of the PXXP, With a three-residue spacing betWeen R778 
and the ?rst proline P881 of the PXXP motif (see, TABLE 
I, beloW). This is one residue longer than that expected for 
a standard class I SH3 ligand. The proline-rich binding 
domain Within the human PARP-1 sequence contains the 
sequence: RIAPPEAPNT (SEQ ID. NO: 35), conforming to 
the classic PXXP motif. 
TABLE I shoWs a selected portion of the sequence 
alignment of PARP family betWeen residues 656e1014 
found Within a loop connecting beta strand 1 and 2 of the 
core ADPRT fold (FIG. 2). Only PARP-1 and PARP-2 
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contain the PXXP SH3 binding core motif, While PARP-3, 
tankyrase and vault-PARP shoW little sequence conservation 
in this loop, Which is not only surface accessible, but also 
lies behind the active site of PARP-1, such that its extension 
residues form part of the PARP-1 active site. 
TABLE I 
Peptide Sequence 
PARP Protein Alignment SEQ ID NO 
PARP-l human GLRIAPPEAPVT—————GYMF: SEQ ID NO 41 
PARP-l mouse GLRIAPPEAPVT—————GYMF: SEQ ID NO 42 
PARP-l rat GLRIAPPEAPVT—————GYMF: SEQ ID NO 43 
PARP-2 human GLRIAHPEAPIT—————GYMF: SEQ ID NO 44 
PARP-2 mouse GLRVAPPEAPIT—————GYMF: SEQ ID NO 45 
PARP-3 human GLRIMPHS ——————— ——GGRV: SEQ ID NO 46 
tankyrase GFDERHAYI —————— ——GGMF: SEQ ID NO 47 
vault PARP APPGYDSVHGVSQTASVTTDF: SEQ ID NO 48 
The ?nding of the PXXP motif prompted an immediate 
search for regions of the PARP-1 sequence With no knoWn 
function, but With a high probability of beta sheet prediction 
using the algorithm of StultZ C M, White J V, & Smith T F, 
Protein Sci. 2(3): 305e14 (1993). Since the structure of 
CF-PARP-l is knoWn, the search focused on the N-terminal 
fragment, Which contains an assigned domain of no clear 
function (C domain). 
We performed a secondary structure prediction of PARP-1 
N-terminal domain, including predictions for beta sheet, 
alpha helix and turns and solvent accessibility. The results 
support the existence of a SH3 domain Within the PARP-1 
C domain. Since most of the PARP-1 domains have been 
mapped, the secondary structure prediction focused on the 
region betWeen the N-terminal Zinc ?ngers and the BRCT 
domain. This region betWeen residues 240 and 400 (human 
sequence) shoWed a 60 reside region With a mostly beta 
sheet prediction Within the PARP-1 C domain (see, FIG. 
1A). 
The sequence of PARP-1 betWeen residues 280e350 Was 
compared With sequences of other SH3 domains of knoWn 
structure obtained from the Protein Data Bank (PDB) data 
base. The Protein Data Bank is operated by Rutgers, The 
State University of NeW Jersey; the San Diego Supercom 
puter Center at the University of California, San Diego; and 
the National Institute of Standards and Technologyithree 
members of the Research Collaboratory for Structural Bio 
informatics (RCSB). FIG. 6 is a sequence alignment of a 
select group of SH3 domains (top 7 sequences) Whose 
structures have been determined and deposited in the PDB 
database. The ?rst three letters of the sequence identi?cation 
indicates the PDB code: 1AEY (SEQ ID NO: 21); 1AOJ_A 
(SEQ ID NO: 22); 1AZE_A (SEQ ID NO: 23); 1AON_B 
(SEQ ID NO: 24); 1ABO_A (SEQ ID NO: 25); 1ARK (SEQ 
ID NO: 26); P53BP (SEQ ID NO: 29). The bottom 6 
sequences are those from the C domain of PARP-1 from 
mouse (P_mussh3; SEQ ID NO: 28), rat (P_ratsh3; SEQ ID 
NO: 29), human (P_humsh3; SEQ ID NO: 30), bovine 
(P_bovsh3; SEQ ID NO: 31), chicken (P_chksh3; SEQ ID 
NO: 32) and Xenopus (P_xensh3; SEQ ID NO: 33). 
FIG. 6 shoWs the conserved sequences among the SH3 
domains. The determination of Which sequences are con 
served, as Well as guidance for the possible substitution of 
an equivalent amino acid for any amino acid in a peptide 
sequence, thereby maintaining the structure and function of 
the polypeptide, is Well-knoWn to those of skill in the 
molecular biological arts (see, Alberts B et al., Molecular 
Biology of the Cell. 3rd ed. (NeW York: Garland Publishing, 
1994); LeWin B, Genes VI. (New York, Oxford University 
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Press, 1997); Lodish H et al., Molecular Cell Biology. 4th 
ed. (New York, W. H. Freeman and Company, 1999); 
Strachan T & ReadA P, Human Molecular Genetics, 2nd ed. 
(New York: John Wiley & Sons, 1999)). These determina 
tions can be performed using commercially available com 
puter programs, such as DNA Strider and Wisconsin GCG. 
These determinations can also be performed using more 
sophisticated molecular modeling software, such as Insight 
II, described in EXAMPLE 3. 
Based on the conserved sequences of the conserved 
sequences of the six PARP-l SH3 domains in FIG. 6, a 
consensus PARP-l SH3 domain can be written as 
DRVXDGMXFGALLPCXECSGQXVFKX 
DAYYCXGDXXAWTKCXXKTQXPXRKXWVX 
PKEFXEIXYL (SEQ ID NO: 1)) 
The sequence comparison of PARP-l C domain with that 
of a select group of SH3 domains with known 3D-structure 
revealed a set of conserved aromatic residues that map to the 
peptide-binding surface of SH3 domains. The sequence 
variability is restricted to three loop regions of the SH3; two 
of them are the RT and n-src loop, which surround the 
peptide-binding surface. The sequence comparison below 
also reveals that PARP-1-SH3 likely belongs to a separate 
subgroup. The ?rst subgroup represented by the top six 
sequences represents the classic SH3 domain with recogni 
tion favoring class I peptides with an arginine residue at the 
N-terminal end of the PXXP motif. The second subgroup is 
represented by P53 binding protein (P53BP), which by far 
has the largest insertions in the n-src loop and the loop 
connecting S3 to S4. The PARP-l vertebrate sequences form 
the third subgroup, which in terms of siZe of its loop is closer 
to subgroup I. 
As shown in FIG. 6, the hydrophobic residues that make 
up the SH3 core are conserved in PARP-l SH3. Five strands 
(S1, S2, S3, S4, S5) form the SH3 domain. A single helical 
region contains a conserved proline at the beginning. 
PARP-l -SH3 differs from other SH3 domain in the lack of 
conservation of the YDF motif (SEQ ID NO: 19) at the 
N-terminal end (see FIG. 5). A break in aromatic conserva 
tion is also found in P53-binding protein SH3 domain, which 
does not conserve the C-terminal aromatic motif FXXPXXY 
(SEQ ID NO: 36). This suggests that at least one set of 
aromatic motifs must be conserved in the SH3 module. 
Moreover, a published random mutagenesis experiment 
had been performed in PARP-l, where Trucco et al., Mol. 
Cell Biochem. 193(1*2): 53*60 (1999) were looking for 
activation de?cient mutants of PARP-l that were still 
capable of binding to DNA and retaining basal level of 
activity. The Trucco experiments of revealed a point muta 
tion within domain C, G313E mutation (SEQ ID NO: 37), 
which generated an “activation de?cient mutant”. Trucco 
suggested that the de?ciency of the G313E mutant was a 
result of either an “induced strong change in the tertiary 
structure of the enZyme or plays an important role in 
self-association and/or in heterodimeriZation with other pro 
teins.” Viewing the Trucco interpretation in light of our SH3 
and SH3-ligand domain assignments, domain C may be 
involved in protein interactions, which is herein proposed to 
be a novel SH3, SH3-ligand interaction. 
Thus, the existence of a PARP-l SH3 domain shows that 
PARP-l can be activated by cytoplasmic proteins, indepen 
dent of DNA damage. Based upon the deduced existence of 
a PARP-1-SH3 and SH3 ligand domains, a model for 
PARP-l activation upon DNA recognition has been formed. 
The model is summariZed in FIG. 1C, which shows that 
DNA recognition by the Zinc ?ngers, Z1 and ZII, triggers 
PARP-l activation, through SH3 and SH3-ligand domains. 
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Since PARP-l activity is known to require dimer formation, 
dimeriZation involves the inter-molecular interaction 
between the SH3 domain of one monomer and the SH3 
ligand of a second PARP-l monomer. Since activation 
depends on DNA binding, this may trigger dimeriZation, as 
shown in FIG. 1B. According to FIG. 1B, dimeriZation 
through PARP-1-SH3 puts the automodi?cation/BRCT 
domain in close proximity to the catalytic domain. FIG. 7 
shows two structural possibilities. 
This approach to understanding the PARP-l mechanism 
of action is a classic one, where the PARP-l domains are 
separated from the full-length protein and the behavior of 
the separate units identi?ed. Understanding how these 
domains function individually enables us to address their 
function in the context of the full length PARP-l and 
determine potential cooperativity between domains during 
PARP-l activation. 
The discovery of the proline-rich sequence in PARP-l 
opens a new area for the design of selective inhibitors of 
PARP-l that focuses on the mechanism of PARP-l activa 
tion and not its catalytic activity. This approach includes the 
generation and use of peptide inhibitors or peptide mimics of 
proline-rich sequence. 
The importance of this ?nding is strengthened by the 
discovery of several PARP-l-like proteins containing a 
highly conserved catalytic domain. However, these PARP-l 
inhibitors have targeted the catalytic domain and as a result, 
all PARP-l inhibitors lack selectivity. By contrast, the 
invention provides methods of selectively targeting PARP-l 
for designing therapeutic compounds that are radio- and/or 
chemosensitiZing, for example, or for developing therapeu 
tic agents for stroke or diabetes type 1. 
Jagtap et al., Criz. Care Med. 30(5):1071*82 (2002) 
developed phenanthridinone PARP-l inhibitors and tested 
them in vivo and in vivo for the ability to reduce PARP 
activation and to protect against various cytotoxic events. 
The compounds were shown to have signi?cant cryoprotec 
tive effects in vitro and signi?cant protective effects in shock 
and reperfusion in vivo. Ha et al., Neurobiol. 7(4):225*39 
(2000), showed that PARP-l over-activation caused by 
cellular insults appears to play a prominent role in stroke and 
other neurodegenerative processes in which PARP-l gene 
deletion and PARP-l inhibiting drugs provide protection. 
Mabley, et al., Br. J. Pharmacol. 133(6):909*19 (2001), 
investigated the role of PARP in mediating the induction of 
diabetes and [3-cell death in the multiple-low-dose-strepto 
Zotocin (MLDS) model of type 1 diabetes. An inhibitor of 
PARP was found to protect mice from MLDS and prevent 
[3-cell loss, in a dose dependent manner. These publications 
provide evidence that the activation of PARP contributes to 
[3-cell damage and death in the MLDS model of diabetes, 
and indicate a use for PARP activation in cytokine-mediated 
depression of insulin secretion and cell viability in vitro. 
The details of one or more embodiments of the invention 
are set forth in the accompanying description above. 
Although any methods and materials similar or equivalent to 
those described herein can be used in the practice or testing 
of the present invention, the preferred methods and materials 
are now described. Other features, objects, and advantages 
of the invention will be apparent from the description and 
from the claims. In the speci?cation and the appended 
claims, the singular forms include plural referents unless the 
context clearly dictates otherwise. Unless de?ned otherwise, 
all technical and scienti?c terms used herein have the same 
meaning as commonly understood by one of ordinary skill 
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in the art to Which this invention belongs. All patents and 
publications cited in this speci?cation are incorporated by 
reference. 
The following EXAMPLES are presented in order to 
more fully illustrate the preferred embodiments of the inven 
tion. These EXAMPLES should in no Way be construed as 
limiting the scope of the invention, as de?ned by the 
appended claims. 
EXAMPLE 1 
PARP-l Bacterial Expression Vectors 
A fragment containing PARP-1-SH3, residues 28(k340 
Was PCR cloned using primers with BamHI and Xhol 
restriction sites. The fragment Was cloned into tWo expres 
sion vectors, Pet28a (Novagen) and PEGX (Stratagene). 
The tWo vectors contain a histidine tag and a GST fusion 
protein respectively. These tWo tags serve tWo purposes: (1) 
for use in a single step puri?cation of PARP-1-SH3 folloWed 
by removal of the tag using a thrombin cleavage site (The 
thrombin used in the cleavage reaction can be removed by 
using biotinylated thrombin); and (2) the PGEX vector 
containing the GST fusion protein also serves the purpose of 
enhancing the solubility of the recombinant protein. 
The fragment can be subcloned into a pTYB(NEB) vec 
tor, Which attaches a chitin binding/intein self-cleaving 
domain. Chong S et al., Gene 192(2): 271*81 (1997). After 
induction With IPTG, the fusion protein is puri?ed using a 
chitin-binding column. Once the fusion protein is attached to 
the column, DTT is added to induce the self-cleaving 
activity of intein. The puri?ed native protein is eluted While 
the intein domain remains attached to the column. 
An SDS PAGE gel has been used to separate the GST 
puri?ed fusion protein and the thrombin cleaved fragment, 
releasing the 6 kDa SH3 fragment. 
Both of these constructs can noW be used to investigate 
their ability to bind to full-length PARP-l using (1) a GST 
pulldoWn assay and (2) a surface plasmon resonance assay 
employing a BIACORE instrument. A PARP-l activation 
assay in the presence of different domains can be used to 
identify interactions necessary for activation. 
EXAMPLE 2 
Structure/ Function Testing 
The binding of PARP-l to DNA strand breaks results in 
its activation by the interaction of SH3 and SH3-ligand 
domains. This model provides the rationale for the devel 
opment of a neW drug discovery paradigm for generation of 
PARP-l inhibitors for cancer therapy. 
Functional Test of the Model Regarding the SH3 and 
SH3-ligand Domains of PARP-l. Directed mutagenesis is 
used to generate single amino acid changes to disrupt the 
peptide recognition surface of the PARP-l SH3 domain and 
the SH3-ligand domain. Disruption of either domain results 
in a PARP-l that is unable to be activated by DNA strand 
breaks. 
Human PARP-l SH3 is mutated at residues that map to a 
conserved, and predominately aromatic surface (L293A, 
P294A, C295A, W318A, W333A, P336A and F339A) 
involved in the recognition of the proline-rich PXXP SH3 
ligand (PPH). The site-directed mutants are designed to 
maintain structural integrity of the SH3 domain, While 
disrupting its ability to interact With the SH3 -ligand found in 
CF-PARP-l (TABLE 1). 
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In particular, the full length PARP-l and its mutants are 
expressed in Sf9 insect cell/baculovirus system and puri?ed 
using an af?nity chromatography on 3-aminobenzamide 
A?-Gel 10, Which Was also used in the crystallization of the 
CF-PARP-l. Decker P et al., Clin. Cancer Res. 5: 1169*72 
(1999). 
Site directed mutagenesis is performed using Quick 
Change® method (Stratagene). All mutations are performed 
on a subclone of PARP-l containing either the catalytic 
fragment of PARP-l or the domain C of PARP-l (see, FIG. 
1A). Each subclone is engineered With unique restriction 
sites at both ends alloWing us to piece together a point 
mutated full length PARP-l. 
The PARP-l activation assay is as described by Rolli V et 
al., Biochemistry 36: 1214754 (1997). The DNA binding 
assay is performed as described by GradWohl G et al, Proc. 
Natl. Acad. Sci. USA 87: 299(L4 (1990). 
Also, the PXXP motif is disrupted With the mutations, 
P881A (SEQ ID NO: 38), P882A (SEQ ID NO: 39) and 
P885A (SEQ ID NO: 40), all of Which disable the PPll 
structure and consequently disable PARP-l activation. The 
ability of PARP-l mutants to bind to DNA and its basal level 
of activity serves as a control that the mutations are not 
disabling as to catalytic activity or DNA binding. 
The mutations in PARP-l SH3 could conceptually gen 
erate three potential phenotypes: (1) a constitutively active 
PARP-l, (2) an activation knockout of PARP-l; or (3) Wild 
type PARP-l (unlikely). Constitutive active mutants Would 
suggest that the C domain keeps PARP-l in the OFF state. 
An activation knockout e?fect suggests either: (a) that 
domain C is vital for turning catalytic activity ON, or (b) that 
the mutation has disrupted PARP-l structure. The latter 
possibility is investigated as shoWn beloW. The observation 
of a Wild type phenotype for all the seven mutations is 
unlikely, since there is experimental data maps an activation 
de?cient mutant of PARP-l to the SH3 domain. 
Structural Analysis by Characterization of the Solution 
Structure of the Wild Type and Site-Directed Mutants of the 
SH3 Domain by Circular Dichroism and Screening for 
Crystallization Conditions. Circular Dichroism (CD) mea 
surements provide a fast, relatively simple and established 
method for estimating the relative content of protein sec 
ondary structure. CD measurements With the puri?ed frag 
ment of PARP-l SH3 support the deduced beta sheet struc 
ture, supporting the fold model and enabling more elaborate 
methods such as X-ray crystallography and/or NMR. The 
CD experiments are also performed on site-directed mutants 
of PARP-l SH3 (see, above). Since these mutations are 
designed to alter surface properties and not the predicted 
SH3, the results provide a control that the mutations have 
not affected the molecular structure of PARP-l SH3. 
The structure determination of PARP-l SH3 using X-ray 
crystallographic techniques provides the ultimate evidence 
of an SH3 fold. 
The predicted SH3 domain of PARP-l and the site 
directed mutants of PARP-l SH3 domain are expressed as a 
GST-fusion protein (PGEX vector, Pharmacia/LKB Tech 
nology) and a polyhistidine-tag (HIS-tag) vector (Pet28c, 
Novagen). The tags are useful for the puri?cation of the 
predicted SH3 domain and can be cleaved off using a 
biotinylated thrombin, enabling the capture of the thrombin 
(Novagen). The CD spectra are measured and program 
CONTIN (Bousquet J A et al., Biochemistry 39, 7722*35 
(2000)) used to extract secondary structure content. 
The expressed PARP-l SH3 peptides are also screened for 
crystallization, to determine the structure using crystallo 
graphic techniques. 3D-structures of the SH3 domains of 
US 7,072,771 B2 
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other proteins are known, thus providing guidance for the 
analysis of PARP-l SH3 structure. 
Structure/Function Test of the Physical Interaction of 
PARP-l SH3 and SH3-ligand Domains By Direct Binding 
Experiments. To shoW that PARP-l contains a functional 
SH3 domain involved in its activation, the SH3 domain 
should be shoWn to bind directly to the SH3 -ligand found in 
CF-PARP-l. 
Binding of the GST-SH3 fusion construct With the cata 
lytic fragment of PARP-l (CF-PARP-l) is assayed using 
glutathione beads to immobilize GST-SH3. Complex detec 
tion are done using Western blots With anti-GST and com 
mercial PARP-l antibodies. CF-PARP-l mutants that dis 
rupt the putative polyproline helix II (PPH) (SH3-ligand 
domain) are used as a negative control. 
Binding assays folloW procedures used for characteriza 
tion of SH3 domains. Mosser EA et al., Biochemistry 37: 
13686495 (1998). The GST and HIS-tags are used to immo 
biliZe the SH3 domain. Then, binding of PARP-l SH3 to 
CF-PARP-l and mutants of CF-PARP-l With alterations in 
the SH3-ligand domain (PXXP motif, FIG. 3) is tested as 
follows: RIAAAEAP (SEQ ID NO:41), RIAPAEAA (SEQ 
ID NO: 42) and RIAAPEAA (SEQ ID NO: 43). Commercial 
antibodies against GST, HIS-tag and CF-PARP-l are used in 
Western blots to identify protein complexes. The ability of 
PARP-l SH3 to interfere or compete With the natural SH3 
ligand is tested by adding increasing amounts of PARP-l 
SH3 to the activation assay of Wild type PARP-l. 
EXAMPLE 3 
Molecular Modeling in Designing PARP-l 
Inhibitors 
Based upon the noW determined structure of the SH3 
domain and SH3-ligand domain of PARP-l, knoWn and 
predicted compounds can be tested by molecular simulations 
for interaction With PARP-l, using InsightII (Molecular 
Visualization (MolViZ) Facility Department of Chemistry 
Indiana University, Bloomington, Ind. USA) and other mod 
eling softWare. 
First, the structure of the PARP-l SH-3domain or the 
PARP-l SH3-ligand domain in a digital format that can be 
used by a molecular modeling computer program. The 
molecular modeling softWare generally provides informa 
tion regarding Which digital format is acceptable for that 
program. Next, the structure of a compound suspected of 
molecularly interacting With the PARP-l SH-3domain or the 
PARP-l SH3-ligand domain is obtained. The “molecularly 
interacting” can be covalent, ionic or other noncovalent 
binding. Guidance for hoW the compound may molecularly 
interact With these domains is provided above. Then, the 
structure of the compound suspected of molecularly inter 
acting With the PARP-l SH-3domain or the PARP-l SH3 
ligand domain in a digital format that can be used by the 
molecular modeling computer program. The molecular 
modeling computer program is operated to determine (1) 
Whether the PARP-l SH-3domain molecularly interacts With 
the compound suspected of molecularly interacting With the 
PARP-l SH-3domain, or (2) Whether the PARP-l SH3 
ligand domain molecularly interacts With the compound 
suspected of molecularly interacting With the PARP-l SH3 
ligand domain, using the instructions provided by the 
molecular modeling softWare and methods knoWn to those 
of skill in the bioinformatics art. Based upon this operation, 
it is possible to identify a compound that interacts molecu 
larly as being a potential therapeutic agent. 
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Guidance for a comparison of structural and dynamic 
properties of di?cerent simulation methods applied to SH3 
can be found in scienti?c publications, including van Aalten 
V M F et al., Biophys. J. 70: 6844692 (1996), Hansson H et 
al., Biochemistry (2001), and Garbay C et al., Biochem. 
Pharmacol. 60(8): 116549 (2000), among others. 
EXAMPLE 4 
Structural/Functional Model of the L613F PARP-l 
Mutant 
To achieve selective targeting of the PARP-l enZyme, We 
investigated the structure of the PARP-l protein and the 
mechanism of PARP-l activation upon DNA damage rec 
ognition. 
The sequence of PARP-l has a unique set of domains, 
including tWo Zinc ?nger DNA binding domain and a 
conserved C-terminal domain similar to the breast cancer 1 
gene (BRCAl), Which is involved in protein-protein inter 
action also called BRCT. Deng C X & Brodie S G, BioEs 
says 22(8): p. 728437 (2000); Bork P et al., Faseb J. 11(1): 
68476 (1997). Also, PARP-l contains a src homology 3 like 
domain (SH3) and SH3 ligand domains. Macias M. J et al., 
FEBS Len. 513(1): 3047 (2002). Furthermore, the G313E 
mutation (SEQ ID NO: 37) interferes selectively With the 
mechanism of activation of PARP-l and maps to the PARP 
1-SH3. 
Based on these lines of evidence We developed a model 
for PARP-l activation upon DNA recognition. Since 
PARP-l activity requires dimer formation, dimeriZation 
should involve the inter-molecular interaction betWeen the 
SH3 domain of one monomer and the SH3-ligand of a 
second PARP-l monomer. This model is a classical 
approach toWards understanding PARP-l mechanism of 
action, since We are ?rst separating the domains from the full 
length PARP-l and then identifying their behavior as sepa 
rate units. By ?rst understanding hoW these domains func 
tion individually, We can then address their function in the 
context of the full length PARP-l protein and determine 
potential cooperativity betWeen domains during PARP-l 
activation. 
Accordingly, We have noW modeled a gain of function 
mutation L613F that maps to the catalytic fragment of 
PARP-l, Whose structure has been determined. (SEQ ID 
NO: 18); RufA et al., Proc. Natl. Acad. Sci. USA. 93(15): 
74815 (1996). This mutation generates a PARP-l protein 
that has a catalytic poWer (km/KM) one order of magnitude 
higher than Wild type PARP-l, in the absence of DNA. 
Miranda EA et al., Biochem. Biophys. Res. Commun. 212(2): 
317425 (1995). The mutation maps to the catalytic fragment 
of PARP-l. The structure of the catalytic fragment of 
PARP-l contains tWo domains, an all alpha domain and a 
conserved ADP-ribosyltransferase domain (ADPRT) (FIG. 
3). The tWo domains interact With each other through a loop 
that contains a PXXP motif (SEQ ID NO: 2), Which should 
be the ligand for the PARP-1-SH3 domain (see, FIG. 1B). 
The mutation L613F maps the all alpha domain of CF 
PARP-l right next to the PXXP loop. We produced the 
structural L613F mutant model utiliZing the knoWn structure 
of the catalytic fragment of PARP-l. The L613F mutation 
involves an amino acid change to a bulkier hydrophobic 
residue. This added bulkiness at position 613 a?cects the 
structure of the neighboring loop that contains our PXXP 
proline rich loop. This structural model is consistent With 
our functional model that suggests that the binding of 
PARP-1-SH3 to the PXXP loop found in the catalytic 
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fragment of PARP-l Which separate the tWo domains (all 
alpha and ADPRT) operates in much the same Way that the 
L613F alteration, Which provides a bulkier side chain, 
affects the activity of CF-PARP-l. 
EXAMPLE 5 
Drugs That are Selectively Designed For PARP-l 
In one embodiment, small peptides With the sequence 
RIAPPEAPV (SEQ ID NO: 7) compete With the natural 
ligand of PARP-l. This sequence is unique to PARP-l and 
should bind poorly to other SH3 domains, such as those that 
are found in cell signaling molecules such as src-kinases. We 
16 
Guidance as to the amount of peptide With sequence 
RIAPPEAPV (SEQ ID NO: 7) that is suf?cient to bind to the 
PARP-l SH3 domain and inactivate the PARP-l or func 
tional fragment thereof is provided by comparison With the 
amount of inhibitors (derivatives of benZamides and fused 
ring heterocycles) used to target the conserved NAD binding 
site (pADPRT domain) of PARP-l, Which present in all of 
the PARP family members. Ruf A. et al., Biochemistry 
37(11): 3893e900 (1998); Tentori L et al., Pharmacol Res. 
45(2): 73e85 (2002); Jacobson M K & Jacobson E L, Trends 
Biochem Sci. 24(11): 415e7 (1999). See also, US. Pat. Nos. 
6,201,020, 6,121,278, 5,587,384, 5,215,738; 5,041,653 and 
5,032,617, each incorporated herein by reference. Assays to 
measure an amount of a compound suf?cient to affect 
. . . . . . 15 PARP-l activity or inhibition are commercially available 
generated bmdmg evldence unhmg the sq?ware SPOT- (Trevigen® PARP Activity Assay Kit and Trevigen® PARP 
SH3’ Whlch has been Shown to predlct the ablhty of pepnde Inhibition Assay Kit‘ Trevigen Inc. 8405 Helgerman Court 
sequences to bind to SH3 domains. Brannetti B et al., J. Mol. Gaithersburg M d {ISA 2087’7) ’ ’ 
gigé'tjl9d3agg2gogi2tggok 851316112115 286? 36 The use of peptide mimics is a strategy that has already 
y ' ’ " ' 0 ' l0 ' ' 20 been successfully used in the design of selective inhibitors 
305415 (2002). 
Natural ligands of other SH3 domain bind their ligand 
PXXP sequence With a predicted score in the range 0.7 to 
0.9. By contrast, by utiliZing the PARP-l SH3 ligand 
sequence, We obtain only a score of 0.6. This result shoWs 
that the PARP-l proline-rich sequence RIAPPEAPV should 
bind poorly to other SH3 sequences, so that peptides With 
sequence RIAPPEAPV (SEQ ID NO: 7) selectively bind to 
PARP-l and inhibit its activity. 
25 
for other SH3 domain proteins. Nguyen J T et al., Chem. 
Biol. 7(7): 463e73 (2000). NoW, the use of peptide mimics 
is a useful strategy for increasing the binding potency of 
peptide ligands to PARP-1-SH3. 
The foregoing description has been presented only for the 
purposes of illustration and is not intended to limit the 
invention to the precise form disclosed, but by the claims 
appended hereto. 
SEQUENCE LISTING 
<l60> NUMBER OF SEQ ID NOS: 48 
<2 10> 
<2ll> 
<2 12> 
SEQ ID NO 1 
LENGTH: 65 
TYPE: PRT 
ORGANISM: Homo sapiens 
<400> SEQUENCE: l 
Asp Arg Val Ala Asp Gly Met Val Phe 
l 5 
Gly Ala 
10 
Leu Leu 
Glu Cys Ser Gly Gln Leu Val Phe Ser Ala 
20 
Lys 
25 
Asp Tyr 
Gly Asp Val Thr Met Val Thr 
35 
Ala Trp Thr Lys 
40 
Cys Lys 
Arg Lys Glu Pro Glu Phe Glu 
50 
Trp Val Thr 
55 
Lys Arg 
60 
Leu 
65 
SEQ ID NO 2 
LENGTH: 4 
TYPE: PRT 
ORGANISM: 
FEATURE: 
NAME/KEY: MODLRES 
LOCATION: (2)..(3) 
OTHER INFORMATION: Any amino acid except Pro 
Homo sapiens 
<400> SEQUENCE: 2 
Pro Xaa Xaa Pro 
1 
Pro Cys Glu 
15 
Tyr Thr 
30 
Cys 
Gln Thr Pro 
Ile Ser Tyr 




























































